Equities research analysts expect that Mylan (NASDAQ:MYL) will report $1.42 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Mylan’s earnings, with estimates ranging from $1.33 to $1.50. Mylan reported earnings of $1.57 per share in the same quarter last year, which indicates a negative year over year growth rate of 9.6%. The business is expected to report its next earnings report after the market closes on Wednesday, February 28th.
According to Zacks, analysts expect that Mylan will report full year earnings of $4.55 per share for the current financial year, with EPS estimates ranging from $4.45 to $4.65. For the next year, analysts forecast that the business will report earnings of $5.34 per share, with EPS estimates ranging from $5.12 to $5.52. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Mylan.
A number of analysts have weighed in on the company. BidaskClub cut Mylan from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 26th. Susquehanna Bancshares reaffirmed a “positive” rating and set a $55.00 price objective (up from $47.00) on shares of Mylan in a research report on Thursday, January 25th. Zacks Investment Research raised Mylan from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. Guggenheim assumed coverage on Mylan in a research report on Tuesday, December 12th. They set a “buy” rating and a $59.00 price objective for the company. Finally, Wells Fargo & Co set a $43.00 price objective on Mylan and gave the stock a “hold” rating in a research report on Thursday, January 18th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have given a buy rating to the stock. Mylan has an average rating of “Buy” and an average price target of $44.89.
In other news, CEO Heather M. Bresch sold 75,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $45.00, for a total value of $3,375,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.69% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. increased its stake in Mylan by 76.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock valued at $106,000 after purchasing an additional 1,475 shares in the last quarter. Rational Advisors LLC purchased a new position in Mylan in the 4th quarter valued at approximately $190,000. BT Investment Management Ltd purchased a new position in Mylan in the 3rd quarter valued at approximately $142,000. Advisor Partners LLC purchased a new position in Mylan in the 4th quarter valued at approximately $214,000. Finally, First Personal Financial Services increased its stake in Mylan by 77.1% in the 4th quarter. First Personal Financial Services now owns 4,839 shares of the company’s stock valued at $205,000 after purchasing an additional 2,106 shares in the last quarter. 76.86% of the stock is owned by hedge funds and other institutional investors.
Shares of Mylan (NASDAQ:MYL) opened at $41.34 on Wednesday. Mylan has a 1 year low of $29.39 and a 1 year high of $47.82. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.95 and a current ratio of 1.46. The firm has a market capitalization of $22,610.00, a P/E ratio of 24.90, a price-to-earnings-growth ratio of 1.14 and a beta of 1.35.
TRADEMARK VIOLATION WARNING: “Analysts Anticipate Mylan (MYL) to Post $1.42 Earnings Per Share” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.thelincolnianonline.com/2018/02/21/analysts-anticipate-mylan-myl-to-post-1-42-earnings-per-share.html.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.